Nakajima E, Hirano T, Konaka C, Ikeda N, Kawate N, Ebihara Y, Kato H
Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan.
Int J Oncol. 2001 Jan;18(1):105-10.
K-ras mutation in sputum was examined using mutant-allele-specific amplification method among 100 primary lung cancer and 15 non-oncological patients. K-ras mutation was detected in 11 out of 59 adenocarcinoma cases (18.6%), 5 out of 32 squamous cell carcinoma cases (15.6%), 2 out of 4 large cell carcinoma cases (50.0%) and 3 out of 15 non-oncological disease cases (20.0%). In the 18 cases of primary lung cancer K-ras mutation was examined in both sputum and the resected specimen of the primary lesion. In 5 cases K-ras mutation in sputum was detected without K-ras mutation in primary lesion. Therefore, these findings suggested that K-ras mutation in sputum may not be directly related to that of the primary lesion.
在100例原发性肺癌患者和15例非肿瘤患者中，采用突变等位基因特异性扩增方法检测痰液中的K-ras突变。59例腺癌患者中有11例（18.6%）检测到K-ras突变，32例鳞状细胞癌患者中有5例（15.6%），4例大细胞癌患者中有2例（50.0%），15例非肿瘤疾病患者中有3例（20.0%）检测到K-ras突变。在18例原发性肺癌患者中，对痰液和原发性病变的切除标本均进行了K-ras突变检测。有5例患者痰液中检测到K-ras突变，而原发性病变中未检测到K-ras突变。因此，这些发现提示痰液中的K-ras突变可能与原发性病变的K-ras突变没有直接关系。
